C3AR1 and stroke disorder: Stokowska et al. (2023) demonstrated that delayed intranasal administration of C3a—initiated seven days post-stroke—attenuates astrocyte reactivity in peri-infarct regions, enhances white matter reorganization, and improves motor outcomes, suggesting a reparative role for C3aR signaling when temporally modulated [20].